COMMUNIQUÉS West-GlobeNewswire

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
20/10/2025
-- Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to [...]
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
20/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today [...]
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
20/10/2025
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH ® in the EU [...]
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
20/10/2025
Leadership team addition to drive strategic long-term value creation and partnering strategy SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field [...]
SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
20/10/2025
SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third [...]
BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
20/10/2025
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
20/10/2025
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics [...]
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
20/10/2025
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex [...]
Health Catalyst to Announce Third Quarter 2025 Operating Results and Host Conference Call on Monday, November 10, 2025
20/10/2025
SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its [...]
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
20/10/2025
New York, NY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the U.S [...]
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
20/10/2025
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) marketing authorization [...]
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
20/10/2025
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets [...]
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
20/10/2025
BioUcenta™ is the first biosimilar of Lucentis (ranibizumab) approved in Africa KIGALI, Rwanda and SAN FRANCISCO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Rwanda Food and Drugs Authority has granted market approval for Bio [...]
Aurora Spine Announces Proposed Warrant Extension
20/10/2025
CARLSBAD, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today [...]
Hapbee Announces R&D of Three New Frequency Wellness Signals for Hunger Management, Allergy Comfort, and Sexual Vitality; Closes Private Placement and Appoints Director
20/10/2025
After powering millions of wellness sessions globally with its signature Sleep, Focus, Calm, Energy, and Strain Relief signals, Hapbee explores adding three transformative frequencies that can broaden the platform’s [...]
BRAVE Trauma Therapist Collective Celebrates 3 Years as Leading Community for Trauma Therapists
20/10/2025
Founded by Dr. Jenny Hughes, the online membership community has supported hundreds of trauma therapists worldwide, impacting thousands of trauma survivors HOUSTON, TX, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BRAVE Providers [...]
EMS HEALTH LLC Unveils New E-Commerce Platform NuGeneLabs.com for Holistic Wellness
20/10/2025
Innovative Online Store Offers Comprehensive Health Solutions and Personalized Wellness Products Miami, FL, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EMS HEALTH LLC, a leader in fitness and holistic wellness services, proudly [...]
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
20/10/2025
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 NEW YORK and AMSTERDAM, [...]
Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
21/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Chardan 9 th Annual Genetic Medicines Conference in New York [...]

Pages